Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,823 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Concentration Clear all
Completed Not applicable Interventional Results available

DoD PTSD November 13 - Information Processing Modification in the Treatment of PTSD

NCT00604045
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Attention Bias Modification (ABM), Attention Control Condition (ACC)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 17, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot)

NCT06410495
View directory record Official record
Conditions
Oppositional Defiant Disorder, Insomnia Chronic
Interventions
NiteCAPP SINCC
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 17, 2026, 9:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Probing the Role of Feature Dimension Maps in Visual Cognition: Impact of Task Demands (Expt 2.1)

NCT06281457
View directory record Official record
Conditions
Basic Science: Visual Attention in Healthy Participants, Basic Science: Neural Representations of Location
Interventions
Stimulus properties: task-defining feature
Other
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

NCT00549653
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Not applicable Interventional

Evaluation of Regulation Focused Psychotherapy for Children

NCT03594253
View directory record Official record
Conditions
Oppositional Defiant Disorder, Oppositional Defiant Disorder in Children
Interventions
Regulation Focused Psychotherapy for Children
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
5 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 4 Interventional

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957
View directory record Official record
Conditions
ADHD, Comorbid Alcohol Abuse
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
El Centro, California • Poway, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Results available

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

NCT00181766
View directory record Official record
Conditions
ADHD NOS
Interventions
Strattera (atomoxetine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

NCT03533556
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-theanine, Caffeine, L-theanine-Caffeine Combination, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

NCT01336218
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
fostamatinib, rifampicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 17, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

Strategy Training for Optimizing Attention for Individuals With Spatial Neglect

NCT07331896
View directory record Official record
Conditions
Stroke, Neglect, Hemispatial
Interventions
Strategy Training, Attention Control
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 17, 2026, 9:12 PM EDT
Recruiting Phase 3 Interventional

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

NCT07717879
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol Dose A, Solriamfetol Dose B, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:12 PM EDT
Not listed Not applicable Interventional

Reading Remediation and Outcomes in Detention

NCT03261076
View directory record Official record
Conditions
Specific Learning Disorder (MeSH Unique ID: D000067559), Dyslexia (MeSH Unique ID: D004410), Conduct Disorder (MeSH Unique ID: D019955)
Interventions
Strategies Enhancing Reading in Older Underperf. Students
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 9:12 PM EDT
Enrolling by invitation No phase listed Observational

Assessing Concentrations of Methadone and Its Metabolites

NCT06835582
View directory record Official record
Conditions
Opioid Use Disorder, Pain
Interventions
Methadone
Drug
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 17, 2026, 9:12 PM EDT
Completed No phase listed Observational

Effect of Gabapentin on GABA Concentration and Emotional Processing

NCT00094510
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 9:12 PM EDT
Completed No phase listed Observational

Deferoxamine for the Treatment of Hemochromatosis

NCT00001203
View directory record Official record
Conditions
Diabetes Mellitus, Heart Disease, Hemochromatosis, Thalassemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 17, 2026, 9:12 PM EDT
Recruiting Phase 4 Interventional

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Not applicable Interventional

Improving the Concentration of MR Contrast in the Arteries

NCT02155218
View directory record Official record
Conditions
Magnetic Resonance Angiography, Contrast Media
Interventions
Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 4 Interventional

Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

NCT00297739
View directory record Official record
Conditions
Aggression
Interventions
Risperidone
Drug
Lead sponsor
Armenteros, Jorge L., M.D., P.A.
Individual
Eligibility
7 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2006 · Synced Oct 17, 2026, 9:12 PM EDT
Suspended Not applicable Interventional

An Study of Transcranial Direct Current Stimulation in Adults With ADHD

NCT02640651
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DC-Stimulator (PLUS version)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Improving Aphasia Using Electrical Brain Stimulation

NCT04963803
View directory record Official record
Conditions
Stroke, Aphasia
Interventions
Active transcranial direct current stimulation (tDCS), Sham transcranial direct current stimulation (tDCS), Language Specific Attention Treatment
Device · Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

NCT01090323
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 17, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Results available

Volume Versus Concentration: Clinical Effectiveness of Single Shot Quadrates Lumborum Block Using Either a High Volume/Low Concentration or Low Volume/High Concentration Injectate for Total Hip Arthroplasty.

NCT04259645
View directory record Official record
Conditions
Acute Pain
Interventions
Drug: Bupivacaine 0.375% 20 mL, Drug: Bupivacaine 0.375% diluted to 0.1875%
Drug
Lead sponsor
Anna Uskova
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 17, 2026, 9:12 PM EDT